Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT00767234 Terminated - Pancreatic Cancer Clinical Trials

Permission to Collect Blood Over Time for Research

Start date: August 2008
Phase: N/A
Study type: Observational

To determine whether biomarkers assessed in blood samples can be used to detect individuals at risk for developing blood clots or worsening of their underlying disease. The ultimate goal of the study is to identify key biomarkers derived from blood that are most characteristic and informative of individuals who will go on to develop a clotting complication.

NCT ID: NCT00766701 Completed - Cervical Neoplasia Clinical Trials

Spectroscopic Evaluation of Cervical Neoplasia

Start date: January 2003
Phase: N/A
Study type: Observational

The overall objective of this study is to evaluate whether fluorescence and reflectance spectroscopy can improve the ability to detect the presence of premalignant lesions on the cervix. The specific aims of the study are: - To compare information obtained from fluorescence and reflectance spectroscopic measurements of the cervix with standard methods for detecting cervical pre-cancers. - To validate previously developed algorithms for discriminating between normal and pre-cancerous tissue based on spectroscopic measurements. - To evaluate the safety of spectroscopic measurement of cervical tissue.

NCT ID: NCT00765570 Terminated - Clinical trials for Advanced Bulky Malignancies

Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy

Start date: February 2003
Phase: Phase 2
Study type: Interventional

Expand clinical literature on the use of Grid radiation with conventional external beam therapy. Vast majority of therapy is for palliative care to provide relief from pain, but has also shown a reduction in the size of tumor mass.

NCT ID: NCT00764621 Completed - Clinical trials for Colorectal Neoplasms

Health Economic Evaluation of Primovist-enhanced Liver MRI

Start date: October 2008
Phase: Phase 4
Study type: Interventional

Patients with a history of colorectal cancer and known or suspected liver metastases who are scheduled for contrast-enhanced tomographic imaging will be included in this study. After randomization to either Primovist-enhanced MRI, extracellular contrast media (ECCM)-enhanced MRI or contrast-enhanced (CE)-CT outcomes and resource needs of the diagnostic work-up and treatment will be evaluated for each of the three imaging modalities. Main objectives of the study are to assess the proportion of patients for whom further imaging is required to come to a therapy decision and to evaluate the proportion of patients with intraoperatively modified surgical plans after Primovist-enhanced MRI as compared to ECCM-enhanced MRI and CE-CT.

NCT ID: NCT00761696 Completed - Neoplasms Clinical Trials

A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

Start date: September 2008
Phase: Phase 1
Study type: Interventional

The primary objectives of the study are: - To determine the safety and the maximum tolerated dose (MTD) of IPI-926 - To examine the pharmacokinetic parameters of IPI-926 and its characterized major metabolite(s) - To recommend a dose and schedule of IPI-926 for subsequent studies

NCT ID: NCT00756223 Completed - Neoplasms Clinical Trials

Phase I Study of BI 831266 in Patients With Advanced Solid Tumours

Start date: November 2008
Phase: Phase 1
Study type: Interventional

The main objective of this trial is to provide safety data in terms of drug-related adverse events for the recommendation of the dose for further trials in the development of BI 831266. Secondary objectives are the collection of antitumour efficacy data and the determination of the pharmacokinetic and pharmacodynamic profile of BI 831266.

NCT ID: NCT00755040 Active, not recruiting - Lymphoma Clinical Trials

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

Start date: October 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder. PURPOSE: This randomized phase I trial is studying how well cyclosporine eye drops work in preventing graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.

NCT ID: NCT00751894 Not yet recruiting - Solid Malignancies Clinical Trials

Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)

MEG-5
Start date: n/a
Phase: Phase 2
Study type: Interventional

Hypothesis : pegfilgrastim at 200 µg/kg between 12 and 18 days after previous chemotherapy provides an efficient stem cell mobilization in children with malignancies Design: phase 2 study. Judgment criterion: percentage of children achieving at least 5x10e6 CD34 cells with a standard apheresis (less than 3 blood volume processed

NCT ID: NCT00750841 Active, not recruiting - Solid Tumors Clinical Trials

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

Start date: September 9, 2008
Phase: Phase 1
Study type: Interventional

Phase I, open study to assess the effect of rifampicin, a marketed drug, on how the body handles the experimental drug cediranib in patients with advanced cancer.

NCT ID: NCT00750737 Completed - Clinical trials for Hematologic Malignancies

Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

Start date: June 2008
Phase: Phase 3
Study type: Interventional

The objective of this study is to compare the safety and efficacy of ABLC versus oral Posaconazole in the prevention of invasive fungal infections in high risk patients with hematologic malignancies or hematopoietic stem cell transplant. Primary objective is to demonstrate the low toxicity rate and low rate of invasive fungal infections associated with ABLC or Posaconazole prophylaxis. Secondary objective will be to compare the cost effectiveness of these two prophylactic regimens.